| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
GSK269962 HCl (also called GSK-269962A HCl), the hydrochloride salt of GSK 269962A, is a selective ROCK (Rho-associated protein kinase) inhibitor with potential antihypertensive and cardioprotective activity. It inhibits ROCK with IC50s of 1.6 and 4 nM for ROCK1 and ROCK2, respectively.
| ln Vitro |
The half-life of GSK269962A against recombinant human ROCK1 is 1.6 nM. A panel of serine/threonine kinases is selectively inhibited by GSK269962A by more than 30 fold[1].
|
|---|---|
| ln Vivo |
GSK269962A is a strong agent that lowers blood pressure. In spontaneously hypertensive rats (SHR), GSK269962A (0.3, 1, and 3 mg/kg; oral gavage) causes a dose-dependent drop in blood pressure. Blood pressure is sharply and significantly lowered[1].
|
| Animal Protocol |
Animal/Disease Models: Male SD (Sprague-Dawley) rats (350-400g)[1]
Doses: 0.3, 1, and 3 mg/kg Route of Administration: po (oral gavage); 12 hrs (hours) Experimental Results: Induced a dose-dependent reduction in blood pressure. |
| References |
| Molecular Formula |
C29H31CLN8O5
|
|
|---|---|---|
| Molecular Weight |
607.07
|
|
| Exact Mass |
606.21
|
|
| Elemental Analysis |
C, 57.38; H, 5.15; Cl, 5.84; N, 18.46; O, 13.18
|
|
| CAS # |
2095432-71-4
|
|
| Related CAS # |
GSK269962A;850664-21-0
|
|
| PubChem CID |
57398146
|
|
| Appearance |
Solid powder
|
|
| Hydrogen Bond Donor Count |
3
|
|
| Hydrogen Bond Acceptor Count |
11
|
|
| Rotatable Bond Count |
10
|
|
| Heavy Atom Count |
43
|
|
| Complexity |
860
|
|
| Defined Atom Stereocenter Count |
0
|
|
| InChi Key |
UYKVMFKKKLLDGL-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C29H30N8O5.ClH/c1-2-37-24-17-25(31-18-23(24)33-28(37)26-27(30)35-42-34-26)41-22-5-3-4-20(16-22)32-29(38)19-6-8-21(9-7-19)40-15-12-36-10-13-39-14-11-36;/h3-9,16-18H,2,10-15H2,1H3,(H2,30,35)(H,32,38);1H
|
|
| Chemical Name |
N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethylimidazo[4,5-c]pyridin-6-yl]oxyphenyl]-4-(2-morpholin-4-ylethoxy)benzamide;hydrochloride
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6473 mL | 8.2363 mL | 16.4726 mL | |
| 5 mM | 0.3295 mL | 1.6473 mL | 3.2945 mL | |
| 10 mM | 0.1647 mL | 0.8236 mL | 1.6473 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA